View ValuationSvas Biosana 将来の成長Future 基準チェック /16Svas Biosana利益と収益がそれぞれ年間6.6%と2.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に9.6% 4.5%なると予測されています。主要情報6.6%収益成長率4.52%EPS成長率Medical Equipment 収益成長13.6%収益成長率2.8%将来の株主資本利益率9.60%アナリストカバレッジLow最終更新日12 May 2026今後の成長に関する最新情報Major Estimate Revision • May 13Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €151.3m to €145.0m. EPS estimate also fell from €1.46 per share to €1.27 per share. Net income forecast to grow 4.9% next year vs 33% growth forecast for Medical Equipment industry in Italy. Consensus price target down from €12.90 to €12.00. Share price fell 3.3% to €8.80 over the past week.Price Target Changed • Jan 10Price target decreased by 10% to €12.40Down from €13.80, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €7.50. Stock is down 6.5% over the past year.Price Target Changed • Aug 07Price target decreased by 16% to €13.80Down from €16.40, the current price target is provided by 1 analyst. New target price is 64% above last closing price of €8.44. Stock is down 25% over the past year. The company is forecast to post earnings per share of €0.87 for next year compared to €0.66 last year.すべての更新を表示Recent updatesUpcoming Dividend • May 25Upcoming dividend of €0.20 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Italian dividend payers (4.5%). Higher than average of industry peers (2.3%).Major Estimate Revision • May 13Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €151.3m to €145.0m. EPS estimate also fell from €1.46 per share to €1.27 per share. Net income forecast to grow 4.9% next year vs 33% growth forecast for Medical Equipment industry in Italy. Consensus price target down from €12.90 to €12.00. Share price fell 3.3% to €8.80 over the past week.お知らせ • May 06Svas Biosana S.p.A., Annual General Meeting, May 20, 2026Svas Biosana S.p.A., Annual General Meeting, May 20, 2026, at 16:00 W. Europe Standard Time.Declared Dividend • Apr 19Dividend reduced to €0.20Dividend of €0.20 is 20% lower than last year. Ex-date: 1st June 2026 Payment date: 3rd June 2026 Dividend yield will be 2.2%, which is higher than the industry average of 1.7%. Sustainability & Growth The dividend has decreased by an average of 8.7% per year over the past 2 years, but has still been somewhat stable with no excessively large reductions to payments. EPS is expected to grow by 20% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Apr 17Svas Biosana S.p.A. announces Annual dividend, payable on June 03, 2026Svas Biosana S.p.A. announced Annual dividend of EUR 0.2000 per share payable on June 03, 2026, ex-date on June 01, 2026 and record date on June 02, 2026.New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€45.7m market cap, or US$53.9m).New Risk • Jan 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (5.2% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€43.4m market cap, or US$50.5m).Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €8.30, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 15x in the Medical Equipment industry in Italy. Total loss to shareholders of 3.3% over the past three years.分析記事 • Oct 31Is Now An Opportune Moment To Examine Svas Biosana S.p.A. (BIT:SVS)?Svas Biosana S.p.A. ( BIT:SVS ), is not the largest company out there, but it led the BIT gainers with a relatively...お知らせ • Jun 26Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million.Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million on June 26, 2025. The consideration of €0.9 million, to be paid over three years, in addition to an earn-out - a variable component linked to the achievement of specific economic results (EBITDA) in the next four years. SVAS has also committed to supporting the growth of MEHOS through a loan of 1 million, to be disbursed within three years. The transaction is expected to close by July 2025. The acquisition and the related financing commitment will be entirely supported by own funds. For the period ending December 31, 2024, Mehos S.R.L. reported total revenue of €5.6 million and EBITDA of €7000.Upcoming Dividend • Jun 02Upcoming dividend of €0.25 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 11 June 2025. Payout ratio is a comfortable 23% but the company is not cash flow positive. Trailing yield: 3.0%. Lower than top quartile of Italian dividend payers (5.4%). Higher than average of industry peers (1.7%).分析記事 • May 16Svas Biosana's (BIT:SVS) Profits May Not Reveal Underlying IssuesThe recent earnings posted by Svas Biosana S.p.A. ( BIT:SVS ) were solid, but the stock didn't move as much as we...お知らせ • May 07Svas Biosana S.p.A., Annual General Meeting, May 20, 2025Svas Biosana S.p.A., Annual General Meeting, May 20, 2025, at 16:00 W. Europe Standard Time.Declared Dividend • Apr 20Dividend reduced to €0.25Dividend of €0.25 is 17% lower than last year. Ex-date: 9th June 2025 Payment date: 11th June 2025 Dividend yield will be 3.4%, which is higher than the industry average of 1.7%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years.お知らせ • Apr 19Svas Biosana S.p.A. announces Annual dividend, payable on June 11, 2025Svas Biosana S.p.A. announced Annual dividend of EUR 0.2500 per share payable on June 11, 2025, ex-date on June 09, 2025 and record date on June 10, 2025.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€39.1m market cap, or US$44.3m).Price Target Changed • Jan 10Price target decreased by 10% to €12.40Down from €13.80, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €7.50. Stock is down 6.5% over the past year.Reported Earnings • Oct 01First half 2024 earnings releasedFirst half 2024 results: Revenue: €59.0m (up 3.8% from 1H 2023). Net income: €2.62m (up 14% from 1H 2023). Profit margin: 4.4% (up from 4.0% in 1H 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Medical Equipment industry in Italy.分析記事 • May 10Svas Biosana's (BIT:SVS) Earnings Are Weaker Than They SeemSvas Biosana S.p.A. ( BIT:SVS ) announced strong profits, but the stock was stagnant. Our analysis suggests that this...New Risk • May 09New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€43.5m market cap, or US$46.9m).Reported Earnings • May 02Full year 2023 earnings releasedFull year 2023 results: Revenue: €121.6m (up 22% from FY 2022). Net income: €5.12m (up 44% from FY 2022). Profit margin: 4.2% (up from 3.6% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Italy.New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€44.0m market cap, or US$46.8m).分析記事 • Dec 09The Returns At Svas Biosana (BIT:SVS) Aren't GrowingIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Price Target Changed • Aug 07Price target decreased by 16% to €13.80Down from €16.40, the current price target is provided by 1 analyst. New target price is 64% above last closing price of €8.44. Stock is down 25% over the past year. The company is forecast to post earnings per share of €0.87 for next year compared to €0.66 last year.Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €97.2m (up 19% from FY 2021). Net income: €3.57m (up 13% from FY 2021). Profit margin: 3.7% (down from 3.9% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Europe.お知らせ • Feb 01+ 2 more updatesSvas Biosana S.p.A. to Report First Half, 2023 Results on Sep 26, 2023Svas Biosana S.p.A. announced that they will report first half, 2023 results on Sep 26, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Oct 06We Think You Should Be Aware Of Some Concerning Factors In Svas Biosana's (BIT:SVS) EarningsFollowing the solid earnings report from Svas Biosana S.p.A. ( BIT:SVS ), the market responded by bidding up the stock...Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €44.7m (up 129% from 1H 2021). Net income: €1.72m (up 74% from 1H 2021). Profit margin: 3.8% (down from 5.1% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Europe.お知らせ • Jun 24Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o.Svas Biosana S.p.A. (BIT:SVS) agreed to acquire 75% stake in the Bormia, trgovina in storitve, d.o.o. for EUR 4.8 million on May 17, 2022. With this transaction, Svas Biosana becomes a leader in the supply of medical devices in the Balkans area. The transaction involves the sale of a total of three shares in Bormia, representing 75% of the relative share capital, by the shareholders Maja Vecerina, Igor Bogatec and Boris Cotic, for a total consideration final amount of EUR 4.8 million, to be paid in full at closing. Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o. on June 23, 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 15+ 2 more updatesSvas Biosana S.p.A. to Report Fiscal Year 2021 Results on Apr 14, 2022Svas Biosana S.p.A. announced that they will report fiscal year 2021 results on Apr 14, 2022お知らせ • Dec 11SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million.SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: €12.5業績と収益の成長予測BIT:SVS - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281548710112/31/2027149838112/31/20261457610112/31/20251427-66N/A9/30/20251387-63N/A6/30/20251357-7-1N/A3/31/20251296-42N/A12/31/20241226-15N/A9/30/2024123606N/A6/30/2024124506N/A3/31/20241235-15N/A12/31/20231225-24N/A9/30/2023117527N/A6/30/2023112459N/A3/31/2023106427N/A12/31/2022100405N/A9/30/2022943-60N/A6/30/2022883-13-5N/A3/31/2022853-8-1N/A12/31/2021823-33N/A9/30/202180326N/A6/30/202179379N/A3/31/2021783810N/A12/31/20207731011N/A12/31/2019100407N/A12/31/2018943N/A9N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SVSの予測収益成長率 (年間6.6% ) は 貯蓄率 ( 3.3% ) を上回っています。収益対市場: SVSの収益 ( 6.6% ) Italian市場 ( 11.2% ) よりも低い成長が予測されています。高成長収益: SVSの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: SVSの収益 ( 2.8% ) Italian市場 ( 5.7% ) よりも低い成長が予測されています。高い収益成長: SVSの収益 ( 2.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SVSの 自己資本利益率 は、3年後には低くなると予測されています ( 9.6 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 12:57終値2026/05/26 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Svas Biosana S.p.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Simone MieliTPICAP MidcapMathias PaladinoTPICAP Midcap
Major Estimate Revision • May 13Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €151.3m to €145.0m. EPS estimate also fell from €1.46 per share to €1.27 per share. Net income forecast to grow 4.9% next year vs 33% growth forecast for Medical Equipment industry in Italy. Consensus price target down from €12.90 to €12.00. Share price fell 3.3% to €8.80 over the past week.
Price Target Changed • Jan 10Price target decreased by 10% to €12.40Down from €13.80, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €7.50. Stock is down 6.5% over the past year.
Price Target Changed • Aug 07Price target decreased by 16% to €13.80Down from €16.40, the current price target is provided by 1 analyst. New target price is 64% above last closing price of €8.44. Stock is down 25% over the past year. The company is forecast to post earnings per share of €0.87 for next year compared to €0.66 last year.
Upcoming Dividend • May 25Upcoming dividend of €0.20 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Italian dividend payers (4.5%). Higher than average of industry peers (2.3%).
Major Estimate Revision • May 13Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €151.3m to €145.0m. EPS estimate also fell from €1.46 per share to €1.27 per share. Net income forecast to grow 4.9% next year vs 33% growth forecast for Medical Equipment industry in Italy. Consensus price target down from €12.90 to €12.00. Share price fell 3.3% to €8.80 over the past week.
お知らせ • May 06Svas Biosana S.p.A., Annual General Meeting, May 20, 2026Svas Biosana S.p.A., Annual General Meeting, May 20, 2026, at 16:00 W. Europe Standard Time.
Declared Dividend • Apr 19Dividend reduced to €0.20Dividend of €0.20 is 20% lower than last year. Ex-date: 1st June 2026 Payment date: 3rd June 2026 Dividend yield will be 2.2%, which is higher than the industry average of 1.7%. Sustainability & Growth The dividend has decreased by an average of 8.7% per year over the past 2 years, but has still been somewhat stable with no excessively large reductions to payments. EPS is expected to grow by 20% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 17Svas Biosana S.p.A. announces Annual dividend, payable on June 03, 2026Svas Biosana S.p.A. announced Annual dividend of EUR 0.2000 per share payable on June 03, 2026, ex-date on June 01, 2026 and record date on June 02, 2026.
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€45.7m market cap, or US$53.9m).
New Risk • Jan 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (5.2% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€43.4m market cap, or US$50.5m).
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €8.30, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 15x in the Medical Equipment industry in Italy. Total loss to shareholders of 3.3% over the past three years.
分析記事 • Oct 31Is Now An Opportune Moment To Examine Svas Biosana S.p.A. (BIT:SVS)?Svas Biosana S.p.A. ( BIT:SVS ), is not the largest company out there, but it led the BIT gainers with a relatively...
お知らせ • Jun 26Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million.Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million on June 26, 2025. The consideration of €0.9 million, to be paid over three years, in addition to an earn-out - a variable component linked to the achievement of specific economic results (EBITDA) in the next four years. SVAS has also committed to supporting the growth of MEHOS through a loan of 1 million, to be disbursed within three years. The transaction is expected to close by July 2025. The acquisition and the related financing commitment will be entirely supported by own funds. For the period ending December 31, 2024, Mehos S.R.L. reported total revenue of €5.6 million and EBITDA of €7000.
Upcoming Dividend • Jun 02Upcoming dividend of €0.25 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 11 June 2025. Payout ratio is a comfortable 23% but the company is not cash flow positive. Trailing yield: 3.0%. Lower than top quartile of Italian dividend payers (5.4%). Higher than average of industry peers (1.7%).
分析記事 • May 16Svas Biosana's (BIT:SVS) Profits May Not Reveal Underlying IssuesThe recent earnings posted by Svas Biosana S.p.A. ( BIT:SVS ) were solid, but the stock didn't move as much as we...
お知らせ • May 07Svas Biosana S.p.A., Annual General Meeting, May 20, 2025Svas Biosana S.p.A., Annual General Meeting, May 20, 2025, at 16:00 W. Europe Standard Time.
Declared Dividend • Apr 20Dividend reduced to €0.25Dividend of €0.25 is 17% lower than last year. Ex-date: 9th June 2025 Payment date: 11th June 2025 Dividend yield will be 3.4%, which is higher than the industry average of 1.7%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years.
お知らせ • Apr 19Svas Biosana S.p.A. announces Annual dividend, payable on June 11, 2025Svas Biosana S.p.A. announced Annual dividend of EUR 0.2500 per share payable on June 11, 2025, ex-date on June 09, 2025 and record date on June 10, 2025.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€39.1m market cap, or US$44.3m).
Price Target Changed • Jan 10Price target decreased by 10% to €12.40Down from €13.80, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €7.50. Stock is down 6.5% over the past year.
Reported Earnings • Oct 01First half 2024 earnings releasedFirst half 2024 results: Revenue: €59.0m (up 3.8% from 1H 2023). Net income: €2.62m (up 14% from 1H 2023). Profit margin: 4.4% (up from 4.0% in 1H 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Medical Equipment industry in Italy.
分析記事 • May 10Svas Biosana's (BIT:SVS) Earnings Are Weaker Than They SeemSvas Biosana S.p.A. ( BIT:SVS ) announced strong profits, but the stock was stagnant. Our analysis suggests that this...
New Risk • May 09New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€43.5m market cap, or US$46.9m).
Reported Earnings • May 02Full year 2023 earnings releasedFull year 2023 results: Revenue: €121.6m (up 22% from FY 2022). Net income: €5.12m (up 44% from FY 2022). Profit margin: 4.2% (up from 3.6% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Italy.
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€44.0m market cap, or US$46.8m).
分析記事 • Dec 09The Returns At Svas Biosana (BIT:SVS) Aren't GrowingIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Price Target Changed • Aug 07Price target decreased by 16% to €13.80Down from €16.40, the current price target is provided by 1 analyst. New target price is 64% above last closing price of €8.44. Stock is down 25% over the past year. The company is forecast to post earnings per share of €0.87 for next year compared to €0.66 last year.
Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €97.2m (up 19% from FY 2021). Net income: €3.57m (up 13% from FY 2021). Profit margin: 3.7% (down from 3.9% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Europe.
お知らせ • Feb 01+ 2 more updatesSvas Biosana S.p.A. to Report First Half, 2023 Results on Sep 26, 2023Svas Biosana S.p.A. announced that they will report first half, 2023 results on Sep 26, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Oct 06We Think You Should Be Aware Of Some Concerning Factors In Svas Biosana's (BIT:SVS) EarningsFollowing the solid earnings report from Svas Biosana S.p.A. ( BIT:SVS ), the market responded by bidding up the stock...
Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €44.7m (up 129% from 1H 2021). Net income: €1.72m (up 74% from 1H 2021). Profit margin: 3.8% (down from 5.1% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Europe.
お知らせ • Jun 24Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o.Svas Biosana S.p.A. (BIT:SVS) agreed to acquire 75% stake in the Bormia, trgovina in storitve, d.o.o. for EUR 4.8 million on May 17, 2022. With this transaction, Svas Biosana becomes a leader in the supply of medical devices in the Balkans area. The transaction involves the sale of a total of three shares in Bormia, representing 75% of the relative share capital, by the shareholders Maja Vecerina, Igor Bogatec and Boris Cotic, for a total consideration final amount of EUR 4.8 million, to be paid in full at closing. Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o. on June 23, 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 15+ 2 more updatesSvas Biosana S.p.A. to Report Fiscal Year 2021 Results on Apr 14, 2022Svas Biosana S.p.A. announced that they will report fiscal year 2021 results on Apr 14, 2022
お知らせ • Dec 11SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million.SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: €12.5